Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. (MDNA.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mdna.to · pe ratio · data through Mar 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Medicenna Therapeutics Corp. (MDNA.TO) measures how much investors pay for each dollar of the company's trailing earnings. MDNA.TO's current PE ratio of N/A is calculated by dividing its stock price of $0.43 by its TTM earnings per share of -$0.16.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-03-31
PE Ratio History
2014 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Medicenna Therapeutics Corp.You MDNA.TO | $30M | N/A | — | -$0.16 |
 Arch Biopartners Inc. ARCH.V | $33M | N/A | — | -$0.02 |
 BioNxt Solutions Inc. BNXT.CN | $53M | N/A | — | -$0.06 |
 Covalon Technologies Ltd. COV.V | $60M | 27.97x | +0.3% | $0.08 |
 Defence Therapeutics Inc. DTC.CN | $29M | N/A | — | -$0.07 |
 Medexus Pharmaceuticals Inc. MDP.TO | $128M | 27.81x | -0.3% | $0.09 |
 MedMira Inc. MIR.V | $42M | N/A | — | -$0.01 |
Industry Average 2 peers with valid PE | — | 27.89x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-03-31Latest FY2025 | — | $-0.15 | — | |
2024-03-31 FY2024 | — | $-0.37 | — | |
2023-03-31 FY2023 | 36.82x | $0.02 | — | |
2022-03-31 FY2022 | — | $-0.42 | — | |
2021-03-31 FY2021 | — | $-0.35 | — | |
2020-03-31 FY2020 | — | $-0.26 | — | |
2019-03-31 FY2019 | — | $-0.18 | — | |
2018-03-31 FY2018 | — | $-0.31 | — | |
2017-03-31 FY2017 | — | $-0.45 | — | |
2016-03-31 FY2016 | — | $-0.08 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Medicenna Therapeutics Corp. (MDNA.TO) measures how much investors pay for each dollar of the company's trailing earnings. MDNA.TO's current PE ratio of N/A is calculated by dividing its stock price of $0.43 by its TTM earnings per share of -$0.16.
Frequently asked questions
MDNA.TO pe ratio · 6 questionsMDNA.TO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.43 and TTM EPS of -$0.16. Data sourced from Financial Modeling Prep via MDNA.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Medicenna Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08